Skip to main content

Table 2 Summary of miRNA expression studies on prostate tumor/serum samples

From: miRNAs associated with prostate cancer risk and progression

miRNA investigated Expression Tissue Reference
let-7a-2,let-7i,16-1,17-5p,20a,21,24-1,25,27a,29a,29b-2,30c,32, 34a,92-2,93-1,95,101-1, 106a, 124a-1,126a-1,135-2,146,149, 181b-1,184,187,191,196-1 197,199a-1, 214,128a, 195,198, 199a-1,199a-2,203,206,214,218-2,223, up tumor Volina, 2006 [45]
202,210,296,320,370,373*,498,503 up tumor Porkka, 2007 [87]
let-7i,25,26a-1/2,31,32,34b,92-1/2,93,99b,106b,125a,181a-1/2,182,188,194-1/2,196a/2,200c, 370, 375,425,449 up tumor Ambs, 2008 [40]
221,222 up tumor Mercatelli, 2008 [42]
16,19b,24,100,125b,141,143,296 up serum Mitchell, 2008 [35]
141,200b, 200c up prostate cells Mitchell, 2008 [35]
221 up PCa cells Mercatelli, 2008 [42]
221 up tumor Spahn, 2009 [91]
9*,15a,16,145,221,222,331,551a up PCa cells Wang, 2009 [90]
128 up PCa cells Khan, 2010 [88]
let-7a,let-7c,let-7f,15b,20a,21,25,26b,30b,106a, 106b, 126*,148a,200c,218,375, up tumor Szczyrba, 2010 [61]
25,93,106b up tumor Poliseno, 2010 [61]
96,182,182*,183 up tumor Schaefer, 2010 [81]
141 up plasma Gonzales, 2011 [133]
182 up Prostate cells Mihelich, 2011 [98]
100,145,191,let7c up tumor Leite, 2011 [138]
9*,141,200b,375,516a-3p up serum Brase, 2011 [115]
21 up plasma Yaman Agaoglu, 2011 [54]
34c up PCa cells Hao, 2011 [95]
20a,21,221 up plasma Shen, 2012 [56]
107,141,301a,326,432,484,574-3p,625*,2110 up plasma Bryant, 2012 [117]
21 up tumor Li, 2012 [55]
let-7b,7,9*,17,19b,20a,21,25,30d,32,92a-1*,93,95,96,106a*,106b, 106b*,130b,142-3p,141*, 148a, 153,182,182*,183,183*,200b*, 200c*, 210,301b,363,375,425,512-3p,583,615-3p,663,801, up tumor Martens-Uzunova, 2012 [48]
let-7a,20a,21,106a,106b,375, up tumor Wach, 2012 [10]
96,124,141,302b,375,378*,489,520d-5p,548a-3p,548c-3p, 875-5p,892b, up serum Nguyen, 2013 [116]
96-5p,183-3p,183-5p up tumor Larne, 2013 [108]
10b,15a,15b,16,18a,18b,20b,25,30c,32,34a,34c-5p, 92a, 122, 124,125a-5p,125b,128a,133b, 134, 135b,146b-5p,148b,181a,181b,181c,184,193a-5p,193b,206,214, 215,301a,372 up tumor Walter, 2013 [110]
19a,188-5p,574-5p,663,939,1224-5p,1225-5p,1249,1915,K12-3,UL70-3p, up tumor He, 2013 [134]
21 up tumor Amankwah, 2013 [102]
32,106b-25,375 up tumor Hudson, 2013 [53]
96-5p,182-5p,183-5p, up tumor Tsuchiyama, 2013 [106]
141,200a,200c,210,375 up serum Cheng, 2013 [120]
19a,19b,20a,20b,26a,26b,29c,106a,125a,125b,135a, 141, 148a,151–5p,174b,193a, 196b, 331-3p,365, 374a, 374b, 1274b, up tumor Lichner, 2013 [135]
19b up tumor Wang, 2014 [124]
182,SNORD78,U17b,U78_s,U78_x up tumor Casanova-Salas 2014 [111]
17*,200b*,210,297,375,501-3p,551b,562 up serum Haldrup, 2014 [113]
345,519c-5p up serum Wang, 2014 [124]
93,106b-25 up PCa cells Liang, 2014 [61]
Let-7a,103,107,130b,106a,26b,451,223,93,24,30c,874,100, 146a up serum Mihelich, 2015 [125]
let-7a-5p,let-7d-3p,let-7d-5p,7-5p,7b-5p,20a-5p,21-3p,25-3p, 29b-2-5p,30d-3p,92a-3p, 92b-3p, 93-3p,96-5p,103a-3p,107, 130b-3p, 182-5p,183-5p,191-5p,196b-5p,200b-3p, 200b-5p, 200c-3p 329, 331-3p,339-3p,342-5p,375,421,423-3p,423-5p, 425-5p, 484, 615-3p,663a,663b,664a-3p, 1248,1260a up tumor Kristensen, 2016 [112]
Let-7a,let-7b,let-7c,let-7d,let-7 g,16,23a,23b,26a,92,99a,103,125a,125b,143,145,195,199a, 199a*,221,222,497 down tumor Porkka, 2007 [87]
let-7b,1-2,34a,145,7-1/2,126,128a,133a-1,145,205,218-2,220,221,329,340,345,410, 487,490,494,499,520 h down tumor Ambs, 2008 [40]
let-7b-g, 26a-b,29a-c,30a-e,99a-b,125a-b,145, 200a-b down tumor Ozen, 2008 [79]
22,24,27a,27b,29a,30e,101,125a-5p,125b,143, 145, 152, 199a-5p,221,223,320,424, down tumor Szczyrba, 2010 [61]
16,31,125b,145,149,181b,184,205,221,222 down tumor Schaefer, 2010 [81]
34c down tumor Hagman, 2010 [92]
34c down PCa cells Hao, 2011 [95]
30c,100,223,346 down Prostate cells Mihelich, 2011 [98]
141 down plasma Yaman Agaoglu, 2011 [54]
143,145,221 down tumor Wach, 2012 [10]
1,15a,16-1,133a down tumor Kojima, 2012 [52]
1,10b,27b,29a,29b,34b,126,126*,130a,133a,133b,139-5p,142-3p,142-5p,143,143*,145,145*, 146a,149,150,155,181b,193b,193b*,204,205,221,221*,222,223,224,328,338-3p, 342-5p, 361-3p 378,378*,455-3p,455-5p,483-3p,485-3p,551b down tumor Martens-Uzunova, 2012 [48]
181a-2* down plasma Bryant, 2012 [117]
31-5p,34c-5p,205-5p,221-3p,222-3p down tumor Tsuchiyama, 2013 [106]
101 down tumor Hudson, 2013 [49]
221,222 down tumor Amankwah, 2013 [102]
23b,26b,30c,155,181d,193a-5p,200b-5p,205,221,221-5p,222,224,335,374a,374b, 455-3p,505 down tumor He, 2013 [134]
145-5p,205-5p,221-5p,409-5p down tumor Larne, 2013 [108]
224 down tumor Mavridis, 2013 [109]
222 down serum Cheng, 2013 [120]
409-3p,623, down serum Nguyen, 2013 [116]
19a,19b down serum Wang, 2014 [124]
34a*,34c-3p,187,221*,221,224, down tumor Casanova-Salas 2014 [111]
1,133b down tumor Karatas, 2014 [55]
1 down Prostate cells Chang, 2015 [46]
15a-5p,16-5p,19b-3p,22-3p,23a-3p,23b-3p,24-3p,26a-5p, 27a-3p, 27b-3p,29a-3p, 29b-3p,30a-3p,30a-5p,30c-5p,30e-3p, 30e-5p, 33a-5p,34a-5p,99a-3p,99a-5p,101-3p, 125b-2-3p, 125b-5p, 127-3p,130a-3p,132-3p,136-5p,143-3p,149-5p, 152, 154-5p,155-5p, 181a-5p,181b-5p,195-5p, 199a-3p,199a-5p, 199b-5p,205-5p, 214-5p,218-5p,221-3p,222-3p, 223-3p,335-5p,338-3p,362-3p,363-3p376a-3p,376c-3p,424-5p, 451a,455-3p, 455-5p,497-5p,502-3p,660-5p down tumor Kristensen, 2016 [112]